Experienced in Langerhans Cell Histiocytosis

Overview

Jeffrey Schwartz is a Pediatric Hematologist Oncology specialist and a Hematologist in Pensacola, Florida. Dr. Schwartz and is rated as an Experienced provider by MediFind in the treatment of Langerhans Cell Histiocytosis. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Infantile Neutropenia, and Dyserythropoietic Anemia and Thrombocytopenia. Dr. Schwartz is currently accepting new patients.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 31 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Langerhans Cell Histiocytosis.

Specialties
Pediatric Hematology Oncology
Hematology
Oncology
Licenses
Pediatric Hematology-Oncology in FL
Languages Spoken
English
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Health Options
  •  Humana
  •  Florida Blue

Locations

5153 N 9th Ave, Pensacola, FL 32504
850-505-4700

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


31 Clinical Trials

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
View 26 Less Clinical Trials
Similar Doctors
Expertise in
5
conditions
Pediatric Hematology Oncology | Hematology | Oncology
Expertise in
5
conditions
Pediatric Hematology Oncology | Hematology | Oncology
1601 Center St, Ste 1s, 
Mobile, AL 
 (53.6 mi)
Languages Spoken:
English

Hamayun Imran is a Pediatric Hematologist Oncology specialist and a Hematologist in Mobile, Alabama. Dr. Imran and is rated as an Advanced provider by MediFind in the treatment of Langerhans Cell Histiocytosis. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Aspiration.

Expertise in
10
conditions
Hematology Oncology | Hematology | Oncology
Expertise in
10
conditions
Hematology Oncology | Hematology | Oncology

Usa Health - Mci Business Services LLC

1660 Spring Hill Ave, 
Mobile, AL 
 (53.6 mi)
Languages Spoken:
English
Accepting New Patients

Thomas Butler is a Hematologist Oncology specialist and a Hematologist in Mobile, Alabama. Dr. Butler and is rated as an Advanced provider by MediFind in the treatment of Langerhans Cell Histiocytosis. His top areas of expertise are Non-Hodgkin Lymphoma, Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Butler is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile